Stage D2前立腺癌患者の内分泌療法におけるretrospectiveにみた予後因子の検討

Abstract

内分泌療法が施行された臨床病期D2 42例について, 臨床的事項と予後との関連を検討した結果, PACP, LDH, Hbの著しい異常値, 治療に対する反応の遅延, そして近接効果などが予後不良因子として考えられた

Of 91 patients with prostatic cancer treated at our Department of Urology, from January 1976 through December 1987, 42 cases of stage D2 cancer treated with endocrine therapy were evaluated retrospectively with regard to clinical parameters and prognoses. The patients with marked increase in the level of the prostatic acid phosphatase (PACP), and the lactate dehydrogenase (LDH) in serum, and marked decrease in volume of hemoglobin (Hb) had a poor prognosis. The patients who took a long time to obtain a favorable response to the therapy had a poor prognosis. The response grade in NPCP criteria at 3 months after the initiation of therapy reflected the prognosis, and showed good correlation to the grade of favorable response.